Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 18 of 0 results

Not applicableUnknownNCT02738593
What this trial is testing

Detection Cell Free DNA in Lung Cancer Patients

Who this might be right for
Non-small Cell Lung Cancer
Sun Yat-sen University 124
Testing effectiveness (Phase 2)Study completedNCT01718847
What this trial is testing

NOV120101 Phase 2 Study in NSCLC Patients With Aquired Resistance to 1st Generation EGFR Tyrosine Kinase Inhibitors

Who this might be right for
Increased Drug Resistance
National OncoVenture 40
Testing effectiveness (Phase 2)UnknownNCT05176665
What this trial is testing

EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers

Who this might be right for
NeoplasmsNeoplasm MetastasisMetastatic Gastrointestinal Carcinoid Tumor
Shanghai EpimAb Biotherapeutics Co., Ltd. 152
Not applicableUnknownNCT02644889
What this trial is testing

EGFR Mutation Detection From Advanced NSCLC Patient Tissue and Plasma in EGFR-TKI Treatment

Who this might be right for
Non-small Cell Lung Cancer
GenoSaber 100
Testing effectiveness (Phase 2)UnknownNCT05326425
What this trial is testing

Lazertinib in Patients With NSCLC With Asymptomatic or Mild Symptomatic Brain Metastases After Failure of EGFR TKI.

Who this might be right for
Lung Neoplasms
Jin Hyoung Kang 40
Not applicableStudy completedNCT01955681
What this trial is testing

A Retrospective, Non-interventional, Multicenter, Observational Chart Review Study to Explore the Clinical Benefits of Retreatment With TKI in the Real World.

Who this might be right for
Locally Advanced or Metastatic EGFR Mutated NSCLC.
AstraZeneca 200
Not applicableUnknownNCT04007835
What this trial is testing

Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

Who this might be right for
NSCLC
Guangdong Association of Clinical Trials 120
Early research (Phase 1)Ended earlyNCT02206763
What this trial is testing

Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
EGFR Mutated EGFR TKI Naive Metastatic NSCLC
Sierra Oncology LLC - a GSK company 11
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07789444
What this trial is testing

Sacituzumab Tirumotecan（Sac-TMT） and Brain Radotherapy for EGFR+ NSCLC With Brain Mets

Who this might be right for
Non-Small Cell Lung CancerBrain Metastases From Non-small Cell Lung Cancer (NSCLC)EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer
Xiaorong Dong 53
Testing effectiveness (Phase 2)Active Not RecruitingNCT04027647
What this trial is testing

Phase 2 Study of Dacomitinib in NSCLC

Who this might be right for
NSCLC Stage IIIBNSCLC Stage IIICNSCLC Stage IV+2 more
National Cancer Centre, Singapore 118
Large-scale testing (Phase 3)Study completedNCT00404924
What this trial is testing

ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures

Who this might be right for
Non-Small-Cell Lung Carcinoma
Genzyme, a Sanofi Company 1,140
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06319950
What this trial is testing

High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases

Who this might be right for
Lung Cancer, Nonsmall Cell
Taizhou Hospital 255
Large-scale testing (Phase 3)Ended earlyNCT02322281
What this trial is testing

TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy

Who this might be right for
Non-small Cell Lung Cancer
Clovis Oncology, Inc. 149
Testing effectiveness (Phase 2)Ended earlyNCT04820023
What this trial is testing

Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment

Who this might be right for
NSCLC
Bridge Biotherapeutics, Inc. 45
Testing effectiveness (Phase 2)Study completedNCT03543683
What this trial is testing

Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC

Who this might be right for
Non-Small Cell Lung Cancer Stage IIIBNon-small Cell Lung Cancer Stage IVEGFR T790M
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 115
Testing effectiveness (Phase 2)Looking for participantsNCT05215548
What this trial is testing

Primary Tumor Resection With EGFR TKI for Stage IV NSCLC

Who this might be right for
NSCLC Stage IV
National Taiwan University Hospital 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT03909334
What this trial is testing

Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Non Small Cell Lung CancerEGFR Gene MutationAdvanced Cancer+1 more
Xiuning Le 160
Testing effectiveness (Phase 2)Study completedNCT01573702
What this trial is testing

Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR)

Who this might be right for
Non Small Cell Lung Cancer
UNC Lineberger Comprehensive Cancer Center 32